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Rationale: Primary ciliary dyskinesia (PCD) is a rare, usually autoso-
mal recessive, genetic disorder characterized by ciliary dysfunction,
sino-pulmonary disease, and situs inversus. Disease-causing muta-
tions have been reported in DNAI1 and DNAH5 encoding outer
dynein arm (ODA) proteins of cilia.
Objectives: We analyzed DNAI1 to identify disease-causing mutations
in PCD and to determine if the previously reported IVS12_3insT
(2193insT) mutation represents a “founder” or “hot spot”
mutation.
Methods: Patients with PCD from 179 unrelated families were stud-
ied. Exclusion mapping showed no linkage to DNAI1 for 13 families;
the entire coding region was sequenced in a patient from the re-
maining 166 families. Reverse transcriptase–polymerase chain reac-
tion (RT-PCR) was performed on nasal epithelial RNA in 14 families.
Results: Mutations in DNAI1 including 12 novel mutations were iden-
tified in 16 of 179 (9%) families; 14 harbored biallelic mutations.
Deep intronic splice mutations were not identified by reverse
transcriptase–polymerase chain reaction. The prevalence of muta-
tions in families with defined ODA defect was 13%; no mutations
were found in patients without a defined ODA defect. The pre-
viously reported IVS12_3insT mutation accounted for 57% (17/30)
of mutant alleles, and marker analysis indicates a common founder
for this mutation. Seven mutations occurred in three exons (13, 16,
and 17); taken together with previous reports, these three exons
are emerging as mutation clusters harboring 29% (12/42) of mutant
alleles.
Conclusions: A total of 10% of patients with PCD are estimated
to harbor mutations in DNAI1; most occur as a common founder
IVS12_3insT or in exons 13, 16, and 17. This information is useful
for establishing a clinical molecular genetic test for PCD.
Keywords: cilia; dynein; dextrocardia; Kartagener syndrome; mutation
(Received in original form March 13, 2006; accepted in final form July 17, 2006 )
Supported by grants GCRC 00046, MO1 RR00046-42, 1 RO1 HL071798, Deutsch
Forschungsgemeinschaft (SFB592 and DFG Om6/2), GIS Maladies Rares A03091,
the ANR Maladies Rares, the Assistance Publique-Hôpitaux de Paris (CRC 96125),
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Primary ciliary dyskinesia (PCD; online Mendelian inheritance
in man [OMIM] 242650) is a heterogeneous genetic disorder
associated with impairment of flagellar and ciliary structure and
function (1–3). PCD has been reported in all major ethnic groups
worldwide (1) and is usually inherited as an autosomal recessive
trait, although other modes of inheritance have been reported
(4, 5). The incidence of PCD is estimated to be 1 in 16,000
individuals (6, 7).
Defective ciliary function in the respiratory tract leads to
impaired mucociliary clearance, resulting in chronic oto-sinu-
pulmonary disease leading to bronchiectasis. Defective nodal
cilial function during embryogenesis leads to situs inversus in
50% of patients with PCD (1, 8–10) and is termed “Kartagener
syndrome” (OMIM 244400) (1). The diagnosis of PCD is impor-
tant especially because of implications for the management of
respiratory tract disease (11); however, establishing the diagnosis
may be difficult. The present “gold standard” diagnostic test is
ciliary biopsy with documentation of abnormal ciliary ultrastruc-
ture by electron microscopy (EM) (3, 11–13). This test is not
easily accessible and requires specialized expertise.
The respiratory cilium is a highly conserved, complex struc-
ture consisting of a 92 arrangement of microtubules and ap-
proximately 250 proteins (14, 15). The force for ciliary beating
is provided by outer dynein arms (ODA) and inner dynein arms
(IDA), which are recognizable structures on transmission EM
images of ciliary cross section (1, 16). The ODA is comprised
of several heavy-, intermediate-, and light-chain dyneins (17,
18). The composition of IDA is highly complex and varies along
the length of the axoneme (13, 19, 20). Mutations in any protein
or structural subunit of cilia could lead to PCD; however, most
patients ( 60–70%) have defective ODAs (1, 3, 21). The re-
cently developed immunofluorescent assay may hold promise
for identifying the ODA defect (22).
No disease-causing gene has been defined from a genome-
wide linkage analysis using multiple families (23). Mutations
have been identified in a small number of patients, in DNAI1
(OMIM 604366) and DNAH5 (OMIM 603335), which encode
an intermediate and heavy chain of ODA, respectively (24–28).
DNAI1 and DNAH5 were identified by candidate gene approach
(24) and “homozygosity mapping,” respectively (27, 29). In rare
instances, mutations in RPGR (involved in X-linked retinitis
pigmentosa) have been identified in male patients with retinal
degeneration cosegregating with PCD (5, 30–33). The purpose
of the current study was to perform a large-scale genetic analysis
for DNAI1 to identify mutations in well characterized, geograph-
ically diverse patients with PCD. This information will be useful
for the development of a clinical molecular genetic test for PCD.
In addition, we analyzed whether the recurring 2193insT
(IVS12_3insT) mutation (24–26) represents a mutational hot
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spot or a common founder. Parts of the current study have been
previously reported as abstracts (34–36).
METHODS
Subjects: Clinical Evaluation
We studied 218 patients with PCD (179 unrelated families) from the
University of North Carolina (UNC) and other specialized PCD centers.
Over half of the patients with PCD (n  112 from 89 families) were
thoroughly evaluated at UNC; the evaluation included medical and
family history, physical examination, sinus and/or chest radiographs,
spirometry, and sputum microbiology (3). Ciliary ultrastructural analy-
sis was carried out on nasal epithelial cells obtained by noninvasive
nasal curettage (3, 37) and processed as described previously (3, 26,
37). Nasal nitric oxide (NO) was measured as described previously (3,
26). Blood or buccal cells were obtained from the proband (and relatives
when possible) for DNA extraction (3, 26, 38). Genomic DNA was
obtained from 106 patients with PCD (90 families) from diverse geo-
graphical locations, including Germany (n  28), France (n  23),
United Kingdom (n  18), Australia (n  11), Italy (n  6), Israel
(n  2), Pakistan (n  1), and the United States (n  1). Ciliary ultra-
structural analysis and compatible clinical phenotype were used for the
diagnosis of PCD. In the absence of ultrastructural analysis, adjunct
tests such as immunofluorescent antibody staining of axonemal proteins,
ciliary beat frequency, or nasal NO measurement were used. This study
was approved by the committee for the protection of the rights of
human subjects at the UNC-Chapel Hill and collaborating institutions,
and written consent was obtained (see online supplement).
Mutation Profiling
All 20 coding exons and intron/exon junctions of DNAI1 were amplified
from gDNA (primers sequences available on request). Polymerase
chain reaction (PCR) amplifications used AmpliTaq polymerase, and
direct DNA sequencing was performed using ABI Prism BigDye primer
Cycle Sequencing Ready Reaction kit on ABI310 or ABI3100 auto-
mated DNA sequencer (Applied Biosystem, Foster City, CA). High
throughput sequencing was carried out at the Genome Sequencing
Center at Washington University (St. Louis, MO). Exclusion mapping
was carried out for 44 families using intragenic polymorphisms of
DNAI1 (see online supplement).
Population Studies
To estimate the allele frequencies in the general population, 10 genetic
variants or mutations (IVS12_3insT, 526_528delGAA, 1177GA,
1212TG, 1222GA, 1307GA, 1490GA, 1612GA, 1644GA,
and IVS191GA) were analyzed in at least 100 chromosomes from
anonymized non-PCD subjects (hemophilia patients) of Caucasian eth-
nicity. Methods used were by restriction digestion or sequencing (see
online supplement).
cDNA Analysis
Total RNA on epithelial cells obtained from the inferior turbinate using
noninvasive nasal curettage (37) was isolated by the TRIzol method
or an RNeasy mini kit (Qiagen, Valencia, CA). First-strand cDNA
synthesis was performed with a SuperScript II RNase kit (Invitrogen,
Carlsbad, CA) for reverse transcriptase–PCR (RT-PCR). RT-PCR fol-
lowed by sequence analysis on DNAI1 mRNA was carried out in 19
patients with PCD from 14 unrelated families using overlapping primer
sets (see online supplement). If multiple fragments were observed on
the agarose gel, the PCR products were cloned into pCR2.1-TOPO
vector (Invitrogen) to separate the alleles for subsequent sequencing.
To determine the effect of the IVS191GA mutation on splicing,
in vitro assay was carried out (see online supplement).
Genotyping of Microsatellite D9S1805 Close to DNAI1
To test for the existence of a possible founder effect associated with
the IVS12_3insT mutation, the genotype of a microsatellite marker
located 0.26 Mb upstream from DNAI1 was determined in eight inde-
pendent patients and in 60 control subjects of Caucasian origin. This
analysis was performed by PCR amplification with the use of a D4-
PA marked primer (available on request), and the fragment size was
analyzed on a CEQ8000 automated sequencer (Beckman Coulter,
Fullerton, CA).
RESULTS
Clinical Phenotype of Patients with PCD
We identified 218 subjects with documented PCD from 179 unre-
lated families. The majority of the families were white (87%).
There was a broad mixture of ethnicity in the remaining families
(see online supplement). Parental consanguinity was noted in 21
(12%) families (as shown in Table E1 in the online supplement).
The clinical phenotypes are representative for that previously
reported in PCD (Table E1): the patients ranged from 0 to 73
yr of age, there was an equal distribution of male and female
patients, and 52% had dextrocardia (Kartagener syndrome).
Most of these patients also had neonatal respiratory distress
(72%), recurrent otitis media (91%), sinusitis (97%), and bron-
chiectasis by radiographic imaging (68%; Table E1). Nasal NO
measurements were available for 100 patients with PCD, and
the mean  SD was 21.7  17.4 nl/min. Values of  100 nl/min
are consistent with PCD, whereas mean values for normal con-
trol subjects were 376  124 nl/min (mean  SD) (3).
Exclusion Mapping
Exclusion mapping using intragenic single nucleotide polymor-
phisms for DNAI1 was carried out in 44 families, when DNA
was available from the affected and/or unaffected siblings and
parents. The proband and the family members were sequenced
for four intragenic polymorphisms, and 13 families were ex-
cluded from linkage to DNAI1 based on defined criteria (listed
in supplements for Methods and Table E2).
Mutation Profiling
We identified 16 unrelated patients with PCD carrying mutations
in DNAI1. Of these 16 subjects, 14 had biallelic, and two had
only one mutation; thus, there were 30 mutant alleles. For each
of the patients carrying mutations, key clinical demographics,
ciliary ultrastructure, and mutations are depicted in Table 1 (see
Table E3 for additional clinical details). For the 14 patients
carrying biallelic mutations, five were homozygous, and nine
were compound heterozygous (Table 1). Of the 30 mutant al-
leles, there were 13 different mutations (Figure 1). One pre-
viously reported mutation (IVS12_3insT) (24–26) was present
on 17 alleles from 12 unrelated patients (Table 1). All the other
mutations were novel: four nonsense, two missense, four splice
defects, one insertion, and one deletion mutation. All the muta-
tions were found only once, except for A538T, which was present
in two unrelated patients (Table 1, Figure 1). Segregation analyses
of the mutations were carried out wherever possible, and biallelic
mutations were always found in trans (Table 1). Segregation
analysis in the first-, second-, or third-degree relatives was carried
out in three families, and the pedigrees were compatible with a
recessive mode of inheritance (Figure 2). Wherever possible,
RT-PCR was carried out in patients carrying a monoallelic muta-
tion (data given below).
Frequency of DNAI1 Mutations
The current data (n  179 families) combined with previously
published reports (n  47 families) (24–26) were used to calcu-
late mutation prevalence. From the total of 226 unrelated pa-
tients with PCD, 22 (10%) harbored mutations, of which 20 had
two mutations (biallelic), giving 42 known mutant alleles. Of
these 42 mutant alleles, 23 (55%) were IVS12_3insT mutation;
82% of all unrelated patients with mutations carried at least
one IVS12_3insT mutant allele. The high prevalence of this
IVS12_3insT mutation suggested a mutational hot spot or a
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TABLE 1. DETAILS OF DNAI1 MUTATIONS IN 16 UNRELATED PATIENTS WITH PRIMARY CILIARY DYSKINESIA
Allele 1 Allele 2
Age at Dynein Arm Amino Acid Amino Acid
Subject Sex Diagnosis (yr) KS† Defect Base Change Exon/Intron Substitution Segregation Base Change Exon/Intron Substitution Segregation
Homozygous
PCD552 F 13 No ODA defect IVS12_3insT Int 1 Splice/trunc Paternal IVS12_3insT Int 1 Splice/trunc Maternal
PCD218 M 70 Yes ODA defect IVS12_3insT Int 1 Splice/trunc nd IVS12_3insT Int 1 Splice/trunc nd
PCD223 M 14 Yes Not available IVS12_3insT Int 1 Splice/trunc nd IVS12_3insT Int 1 Splice/trunc nd
OP121 II:1 F 15 Yes ODA defect IVS12_3insT Int 1 Splice/trunc nd IVS12_3insT Int 1 Splice/trunc nd
UCL64 II2 F 4 Yes ODA defect IVS12_3insT Int 1 Splice/trunc nd IVS12_3insT Int 1 Splice/trunc nd
Compound heterozygous
PCD455 F 40 Yes ODA defect IVS12_3insT Int 1 Splice/trunc nd IVS7–2AG Int 7 Splice/trunc nd
OP-71 II:1 F 20 No ODA defect IVS12_3insT Int 1 Splice/trunc nd 874CT Ex 10 Q292X nd
D78X1 M 40 No ODA defect IVS12_3insT Int 1 Splice/trunc nd IVS10–4_7del Int 10 Splice nd
PCD930 F 10 No ODA defect IVS12_3insT Int 1 Splice/trunc Maternal 1490GA Ex 16 R468_K523del Paternal
UCL3 II:2 F 5 No ODA defect IVS12_3insT Int 1 Splice/trunc nd 1612GA Ex 17 A538T nd
PCD749* M 8 No ODA defect IVS12_3insT Int 1 Splice/trunc Paternal 1926_1927insCC Ex 19 I643PfsX48 Maternal
PCD630 F 1.5 Yes ODA defect 1212TG Ex 13 Y404X Maternal 1222GA Ex 13 V408M Paternal
D32X1 M 10 No ODA defect 1307GA Ex 13 W436X Maternal IVS191GA Int 19 A607_K667del Paternal
PCD327 M 2 Yes ODA defect 1612GA Ex 17 A538T Maternal 1644 GA Ex 17 W548X Paternal
Heterozygous
PCD480 F 37 Yes ODA defect IVS12_3insT Int 1 Splice/trunc nd WT none WT None
F-725 II:3 F 44 No ODA defect 463delA Ex 6 T155LfsX18 Paternal WT none WT None
Definition of abbreviations: Ex  exon; Int  intron; KS  Kartagener syndrome; nd  not determined; ODA  outer dynein arms; splice/trunc  splice mutation
leading to insertion of intron 1 sequences in the message, thus causing truncated protein.
* Patient was half-Caucasian/half-Hispanic ethnicity; all the remaining patients were of Caucasian ethnicity.
† If dextrocardia was present, patients were termed as having Kartagener syndrome. There was no known parental consanguinity in any of these families.
founder effect (see specifics below). A cluster of mutations was
noted in exons 13, 16, and 17, where 12 of 42 mutant alleles
resided (Figure 1); 46% of the families carried at least one
mutant allele in these three exons. Indeed, 21 (96%) of the 22
Figure 1. Distribution of novel and published DNAI1 mutations. (A )
Genomic organization of human DNAI1 as shown previously (24). The
20 exons are indicated by the boxes containing exon numbers (E#).
Shaded boxes represent untranslated regions. The locations of the start
and stop codons and polyadenlylation signal are shown. The number
of the first codon in each exon is indicated; exons beginning with the
second or third base of a codon are indicated by subscript 2 or 3,
respectively. The exons are drawn to scale, and intron–exon boundaries
are denoted by closed triangles. Five conserved tryptophan and aspartic
acid (WD) repeat regions are shown on the top of the genomic structure,
and the codon number for the start and end of each WD repeat box
is indicated. (B ) Schematic drawing of DNAI1 and the position of all
identified mutations are indicated. The number of mutant alleles is
indicated in the parentheses. Novel mutations that were identified in
the current study are italicized and indicated in red. Founder mutation
is in the box; shaded exons indicate a mutation cluster.
unrelated patients carrying mutations would have been detected
by analysis restricted to exons 13, 16, and 17 and IVS12_3insT
mutations. From these 21 patients, biallelic mutations would
have been picked up in 15 (68%) unrelated patients.
Correlation of Genotype with Ultrastructure
Genetic heterogeneity poses a significant challenge to large-scale
genetic testing. One way to address this problem is to carefully
categorize patients by the type of ciliary ultrastructural abnor-
mality (e.g., ODA vs. IDA defects) and test for genes known
to be associated with these specific dynein arm defects. Ciliary
ultrastructure analysis was available from 152 unrelated patients,
and we found that most (79%) of our patients with ciliary EM
analysis had an ODA defect, whereas 13% had isolated IDA
defect (Table E1) (EM images are not shown). Overall, 9% of
our patients with PCD (n  16 of 179) had DNAI1 mutations,
and 13% (15 of 120) patients with a defined ODA defect had
DNAI1 mutation. None of the 32 patients with PCD devoid of an
ODA defect had a DNAI1 mutation (Table 2); thus, mutations in
DNAI1 were noted exclusively in association with ODA defect
(Table 2). Combining the present study and all previous reports
(24–26), DNAI1 mutations are present in 10% (22 of 226) of
unrelated patients with PCD and in 14% (19 of 134) of patients
with PCD with a known ODA defect (Table 2).
Population Studies
To test whether defined mutations are disease-causing for the
PCD phenotype or represent benign polymorphisms, we deter-
mined the frequency of all missense and some of the splice and
nonsense mutations in the general population by analyzing over
100 control alleles; none of the control chromosomes car-
ried any of the tested mutations (Table 3). Although 100 chro-
mosomes were analyzed earlier to define the frequency of
IVS12_3insT mutation (24), we studied an additional 382 al-
leles and found that none carried this mutation.
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Figure 2. Segregation analysis from extended families
demonstrating recessive inheritance of the DNAI1 mu-
tations. (A ) Proband (PCD552) was homozygous for
the previously reported IVS12_3insT mutation. The
parents, a paternal uncle, a paternal aunt, two maternal
aunts, and the maternal grandmother were found to
be carriers. (B ) Proband 630, who had primary ciliary
dyskinesia with dextrocardia (Kartagener syndrome), was
compound heterozygous for the novel mutations in exon
13. Segregation analysis showed that the 1212GA
(V408M) mutation was inherited from the father and
that a paternal uncle was a carrier. The 1222TG
(Y404X) mutation was inherited from the mother, and
a maternal aunt, the maternal grandmother, and the
maternal great grandmother were carriers. (C ) Proband
749 was compound heterozygous, carrying one novel
mutation in exon 19 and a previously reported
IVS12_3insT mutation. His unaffected sibling was a
carrier of the novel exon 19 mutation; this mutation
was inherited from the mother, who inherited it from
her mother (maternal grandmother of the proband).
The IVS12_3insT mutation was inherited from the
father; two paternal uncles and the paternal grand-
father were also carriers.
Polymorphisms and Variants of Unknown Significance
During the current study, we found several polymorphisms that
had been noted previously, and their reference sequence num-
bers (www.ncbi.nlm.nih.gov/SNP/) are presented in Table E4.
We detected two variants of unknown significance (1177GA
[V393M] and 526_528delGAA [176delE]) on one allele of two
unrelated patients with PCD. Full gene sequencing did not reveal
another mutation on the trans allele (see online supplement for
details).
cDNA Analysis
Because deep intronic mutations can be missed by genomic DNA
sequencing (39), we performed RT-PCR for DNAI1 followed
by agarose gel electrophoresis and sequencing on nasal epithelial
RNA from 14 patients from 12 unrelated families. No aberrant
fragments on the agarose gel or additional mutations by se-
quence analysis were identified in any of these patients (Table
4). For one patient (PCD480) who was heterozygous for
IVS12_3insT splice mutation, genomic DNA sequencing did
not reveal any additional mutation. Further analysis of the cDNA
from this patient confirmed aberrant splicing and premature
termination signal due to the IVS12_3insT mutation, as re-
ported previously (24), but did not reveal any additional splicing
defect on the trans allele. Another patient with PCD (PCD930;
TABLE 2. FREQUENCY OF DNAI1 MUTATIONS OBTAINED FROM CURRENT AND PUBLISHED DATA
Number of Families with at Families with at Least One
Study Distribution of Families Number of Families Least One Mutation Mutation (% )
Current Total # of families 179 16 9
Current Total # of families with ODA defect 120 15 13
Published* Total # of families 47 6 13
Published* Total # of families with ODA defect 14 4 29
Combined Total # of families 226 22 10
Combined Total # of families with ODA defect 134 19 14
Combined Total # of families with defined 32 0 0
ciliary defects other than ODA
Definition of abbreviation: ODA  outer dynein arms.
* From References 24–26.
Table 4) was a compound heterozygote for the IVS12_3insT
(maternal) and 1490GA (paternal) mutations. Because the
mutation 1490GA is located at the splice site, we checked for
its effect on splicing. Analysis of maternal RNA confirmed the
splicing defect due to IVS12_3insT mutation. Analysis of pa-
ternal RNA revealed two molecular species on agarose gel, one
of the expected size of 419 bp, and a smaller 251-bp fragment,
not present in the control sample. Sequencing revealed that the
419-bp fragment coincides for the wild-type sequence. Sequencing
the smaller fragment revealed the aberrant splice product lead-
ing to in-frame deletion of 56 amino acids, which comprise exons
15 and 16 (R468_K523del) (Table 4, Figures 3A and 3B). The
consequence of the IVS191GA splice mutation (present in
patient D32X1) on the processing of DNAI transcript was deter-
mined using an in vitro splicing assay. Results demonstrated that
it causes aberrant splicing of DNAI1 transcript, resulting in an
in-frame deletion (61 amino acids) of exon 19 (A607_K667del;
Table 4, Figure 3C).
Founder Effect
Given the relatively high frequency and wide geographic distri-
bution of the IVS12_3insT mutation among patients with PCD,
we wondered whether the IVS12_3insT allele has a common
origin or reflects the existence of a mutational hotspot in the
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TABLE 3. POPULATION FREQUENCY OF MUTATIONS/VARIANTS IN DISEASE-FREE INDIVIDUALS
Subjects Alleles Wild-Type Hetero
Analyzed Analyzed Alleles zygous Alleles Mutant Allele Carrier
Mutation (n ) (n ) (n ) (n ) Frequency Frequency
IVS12_3insT [splice/truncating]* 191 382 382 0 0 0
526_528delGAA [176delE] 54 108 108 0 0 0
1177GA [V393M] 197 394 394 0 0 0
1212TG [Y404X] 56 112 112 0 0 0
1222GA [V408M] 56 112 112 0 0 0
1307GA [W436X] 54 108 108 0 0 0
1490GA [R468_K523del] 111 222 222 0 0 0
1612GA [A538T] 113 226 226 0 0 0
1644GA [W548X] 113 226 226 0 0 0
1657_1668del [T553_F556del]* 113 226 226 0 0 0
IVS191GA [splice] 55 110 110 0 0 0
* The prevalence of this previously reported mutation by others (24, 25) was carried out in the current study.
DNAI1 gene. To address this issue, we analyzed a microsatellite
marker (D9S1805) located 0.26 Mb upstream of DNAI1 in eight
unrelated patients with PCD, two of whom were homozygous for
the mutation and six of whom were heterozygous (i.e., compound
heterozygotes). These unrelated patients originated from differ-
ent geographic regions: four from the United States, two from
France, and two from Germany. This analysis showed that these
patients shared the same D9S1805 allele, characterized by
19-CA repeats. This allele was heterozygous in all patients except
for two, who were homozygous for the IVS12_3insT mutation
and for the 19-CA allele. In addition, a similar analysis per-
formed in a parent carrying the IVS12_3insT mutation on one
allele showed a direct association of this mutation with the 19-CA
allele at the D9S1805 locus. Moreover, the genotype of the
TABLE 4. REVERSE TRANSCRIPTASE–POLYMERASE CHAIN REACTION AND cDNA ANALYSIS OF
DNAI1 IN PATIENTS WITH PRIMARY CILIARY DYSKINESIA
Subject Family Age at Dynein Arm DNAI1 cDNA
Number Number Sex Diagnosis (yr) KS|| Defect NO (nl/min) DNAI1 gDNA Sequence Sequence
3 1 F 40 No IDA 13 No mutation WT
10 2 F 51 Yes IDA na No mutation WT
16 3‡ F 27 No ODA 3 No mutation WT
57 7*‡ M 9 No ODA 2 No mutation WT
58 7*‡ M 4 Yes ODA 7 No mutation WT
144 18‡ F 30 Yes ODA 12 No mutation WT
145 18‡ M 33 No ODA 4 No mutation WT
157 21 F 12 Yes IDA 2 No mutation WT
158 22 F 73 No ODA 2 No mutation WT
159 22 F 63 Yes ODA 10 No mutation WT
274 46*† M 29 Yes ODA 43 No mutation WT
436 74 F 33 Yes ODA 19 No mutation WT
440 76 M 56 Yes ODA 20 No mutation WT
564 89 F 59 Yes IDA 12 No mutation WT
480 83 F 37 Yes ODA 21 IVS12_3insT / Aberrant
930 150 F 10 No ODA 13 IVS12_3insT /, 1490GA / na
957§¶ 150 F — — — — 1490GA / Aberrant
931§¶ 150 M — — — — IVS12_3insT / Aberrant
D32X1 D32 M 10 No ODA na IVS191GA / Aberrant**
Definition of abbreviations: IDA  inner dynein arms; KS  Kartegener syndrome; na  not available; NO  nasal nitric oxide;
ODA  outer dynein arms; WT  wild type.
* Parental consanguinity was noted for Families 7 and 46.
† All the families were of Caucasian origin except Family 46.
‡ Families published earlier and were wild type by genomic DNA sequencing (26).
§ PCD 957 and PCD 931 were the unaffected father and mother of an affected individual (PCD930), respectively.
|| Patients with dextrocaridia were termed as having Kartegener syndrome.
¶ For PCD480, PCD931, PCD957, and D32X1, mRNA analysis showed aberrant message consistent with the results obtained
on genomic DNA sequencing.
** In vitro splicing assay was carried out (see RESULTS).
D9S1805 marker on the trans allele was found to be different
among six compound heterozygous patients (data not shown).
To estimate the frequency of the 19-CA D9S1805 allele in the
general population, the D9S1805 marker was genotyped in 60
independent control subjects. Nine different alleles were identi-
fied among these 120 chromosomes (Figure E1); the 19-CA allele
represented 17.5% of all tested chromosomes.
DISCUSSION
PCD is a genetically heterogeneous disease associated with ab-
normal ciliary ultrastructure and function. Before this study was
done, disease-causing mutations had been described in two genes
(DNAI1 and DNAH5) encoding ciliary outer dynein arms in a
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Figure 3. Effect of the 1490GA and IVS191GA muta-
tions on mRNA. (A ) Electropherogram showing the effect
of the 1490GA mutation on the DNAI1 transcript and
the cDNA sequence of the wild-type (top and bottom) and
mutant (middle) DNAI1 alleles. RNA from the parents was
available for the cDNA analysis. cDNA amplification from
the father, who carried a 1490GA transition, generated
a 419-bp (normal size) and a 251-bp fragment, whereas
only a 419-bp fragment was obtained from the control
subject. In the presence of the 1490A allele, exons 15 and
16 are deleted from the message, leading to the in-frame
deletion of 56 amino acids (R468_K523del). Exons are indi-
cated as E#. (B ) Schematic representation of the 1490GA
splicing mechanisms leading to the normal (top) and aber-
rant (bottom) DNAI1 transcript. The size of the normal (top)
and mutant (bottom) reverse transcriptase–polymerase
chain reaction (RT-PCR) products generated with forward
primer (FP) and reverse primer (RP) (arrows) are indicated
(see online supplement). Exons are indicated as E#. Closed
arrowhead indicates the mutation in the genomic DNA.
(C ) Schematic representation of the splicing mechanisms
leading to normal (top) and abnormal (bottom) DNAI1 tran-
scripts, from the corresponding genomic DNA fragments
(middle); the 3 untranslated region is shown as a shaded
area. The size of the normal (top) and mutant (bottom)
RT-PCR products generated with primers P5 and P7
(arrows) are indicated. The IVS191GA mutation (closed arrowhead) results in abnormal splicing with the generation of a small product
(238 bp) lacking exon 19; this would lead to an in-frame deletion of the 61 amino acid residues (A607_K667del) encoded by exon 19. Normal
splicing results in the generation of a 421-bp product (see online supplement). Exons are indicated as E#.
small number of patients with PCD (24–27). However, geno-
type–phenotype correlations and the prevalence of mutations in
these genes have not been investigated. We undertook a muta-
tion analysis of DNAI1 in a large number of well characterized
patients with PCD to test for the correlation of mutations with
ciliary ultrastructural defects (ODA versus other defects) and
clinical phenotype and to define the prevalence of DNAI1 as a
disease-causing gene in PCD. Determining the prevalence and
distribution of mutations in DNAI1 is essential if a clinical molec-
ular genetic screening test for PCD is to be developed. Because
PCD is a rare genetic disorder, we obtained DNA samples from
six geographically different cities to increase the number of pa-
tients tested. All specimens came from the specialized PCD
centers that are experienced with PCD diagnosis using estab-
lished methods. The majority of the patients (141 of 179) had
specific ultrastructural defects in cilia (Table E1). In addition,
the patients without the defined ultrastructural abnormalities
were included if they had a strong clinical phenotype, including
oto-sinu-pulmonary disease, situs abnormalities, bronchiectasis,
neonatal respiratory distress in term neonates, history of infertil-
ity, low nasal NO, or abnormal ciliary beat frequency. A case
report on a patient with PCD and normal dynein arms has been
reported previously (40).
Our current estimates of 218 subjects from 179 unrelated
families indicate that approximately 9% of all patients with PCD
have disease-causing mutations in DNAI1 and that approxi-
mately 13% of patients with PCD with ODA defects have
DNAI1 mutations (Table 2). None of the 32 unrelated patients in
the current study without defined ODA defects had any DNAI1
mutation. Thus, DNAI1 mutations are detected exclusively in
association with the ODA defects. Similar observations have
been made in Chlamydomonas, where IC78 (ortholog of
DNAI1) mutations lead to ODA defects in flagella (17). We
also observed a similar prevalence of mutations in DNAI1 when
we combined our current study with three previous studies (24–
26) involving 47 families (10% of all the 226 families had DNAI1
mutations, and of those 14% with a known ODA defect harbored
DNAI1 mutations; Table 2). We believe that this observation is
a realistic frequency and that there is no ascertainment bias
because all 89 unrelated patients with PCD evaluated at UNC
were sequenced without preselection, and mutations were seen
in 9% (n  8 patients). In addition, the current study shows
that 14% of patients with PCD with defined ODA defects have
mutations in the DNAI1, and because approximately 66% of
patients with PCD present with ODA defects (1, 3, 21), approxi-
mately 9% of patients with PCD are likely to have mutations
in DNAI1 gene.
The use of polymorphisms(s) to “exclude” families is useful
in a genetically heterogeneous disorder like PCD, especially
when dealing with the large genes, because it reduces the need
for full gene sequencing in a large number of subjects. During
this study, we found nine polymorphisms that were useful for
exclusion mapping because they permitted us to exclude 13 fami-
lies from linkage to DNAI1.
The pattern of inheritance of DNAI1 mutations in PCD
is autosomal recessive (Figure 2). Of 22 patients with DNAI1
mutations from the current and previous studies (24–26), 20 had
biallelic mutations (five patients were homozygous, and nine
patients were compound heterozygous). Furthermore, the segre-
gation pattern, if available (Table 1 and References 24–26),
showed that these mutations were transallelic. In two patients
from the current study, only monoallelic mutations were ob-
served. In these two patients, it is likely that the mutation on
the trans allele was missed because only genomic DNA sequence
analysis was performed. There is no clinical evidence of domi-
nant inheritance in these two patients because a parent from each
of these patients carried the same mutation but was clinically
unaffected. In addition, one patient carried the common muta-
tion in the heterozygous state, and we know that this mutation
segregates in a recessive manner. Although we have not observed
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evidence for a digenic pattern in PCD, it cannot be ruled out.
There are other genetically heterogeneous disorders where this
mode of inheritance has been described (41–43).
The type of mutations in DNAI1 varied. Of the 42 mutant
DNAI1 alleles from 22 unrelated patients from current and pre-
vious studies (24–26), 18 different mutations have been de-
scribed, including frameshift/stop mutations, base substitutions,
and splice mutation. Twelve of the mutations described in the
current study are novel mutations (Figure 1). There were two
missense variants (V408M and A538T), which we believe are
likely to be disease-causing mutations because (1) one of the
variants (A538T) was found to be present in two unrelated
families, (2) segregation analysis showed that they were transal-
lelic with respect to the second mutation, (3) both variants in-
volved residues that are highly conserved across the species and
belong to the conserved tryptophan and aspartic acid (WD)
repeat domain of the gene, and (4) neither variant was detected
in more than 100 control chromosomes from the general popula-
tion (Table 3). Similarly, none of the splice mutations was found
in any of the control chromosomes (Table 3). Although mutations
were present throughout the DNAI1, most mutations occurred
in intron 1 (IVS12_3insT was present in 55%) and in exons 13,
16, and 17 (29% of the mutant alleles). Moreover, nearly half of
the families (46%) carried at least one mutant allele in these three
exons. Having a high prevalence of mutations in discrete regions
(intron 1 and exons 13, 16, and 17) of DNAI1 will aid in the
development of the clinical screening panel for PCD.
The status (mutation vs. polymorphism) of two heterozygous
variants (526_528delGAA [176delE] and 1177GA [V393M])
discovered during this study is uncertain. Both variants are evolu-
tionarily conserved among some species, and they were not pres-
ent in control chromosomes from the general population (108
chromosomes for 176delE and 394 chromosomes for V393M),
suggesting that they may be true mutations. However, it seems
more likely that these are polymorphisms for several reasons:
(1) a patient who carried these variants did not have an ODA
defect (based on EM data), and mutations in DNAI1 have been
associated with ODA defects; (2) a patient who carried 176delE
in a heterozygous state was born to consanguineous parents,
and such a patient would likely depict “identity by descent” and
hence homozygosity for the mutations or polymorphisms at the
disease locus; and (3) in rats, methionine is used at the equivalent
codon of V393M, suggesting that methionine is the normal vari-
ant and hence V393M represents a rare polymorphism (see on-
line supplement).
We also observed the consequence of three splice mutations
on mRNA levels. We confirmed that the IVS12_3insT muta-
tion causes aberrant splicing, as previously reported (24). An-
other mutation, 1490GA, predicts an amino acid substitution;
however, we demonstrated that it also affects splicing, leading
to in-frame deletion of exons 15 and 16 (56 amino acids). Finally,
a splice mutation in intron 19 resulted in an in-frame deletion
of exon 19 (61 amino acids). Although approximately 15% of
the known disease-causing mutations are splice mutations (44),
we found no (deep intronic) mutations by the analysis of RT-
PCR products (Table 4).
The mutations in DNAI1 seem to be most common in white
individuals with PCD. Combining data from the current study
with previous studies (24–26), ethnicity information is available
on 182 unrelated patients with PCD (364 alleles). Most of the
364 alleles were in patients with Caucasian origin (315 alleles),
and 34 alleles carried DNAI1 mutations (11%). Of the alleles
from the patients of non–Caucasian ethnicity (n  47 alleles),
only one allele carried a DNAI1 mutation (2%). The non–
Caucasian dataset is small but suggests that DNAI1 mutations
may be found more commonly in patients with a Caucasian
ethnicity. One reason for DNAI1 mutations in white patients
could be the fact that the IVS12_3insT mutation was present
in 55% (23 of the total 42) of the mutant alleles; moreover, 82%
(18 of 22) of unrelated patients had IVS12_3insT on at least
one allele. Based on the high frequency of the IVS12_3insT
mutation, founder effect analysis was carried out, and several
lines of evidence strongly suggest the presence of a founder
effect. First, a careful examination of the nucleotide environment
did not reveal structural features that would favor the insertion
of one base pair at this position. Second, all the patients who
carried this mutation and who were genotyped at the closely
linked D9S1805 marker were shown to carry the same polymor-
phic allele bearing 19-CA repeats. The association of the disease-
causing mutation with the 19-CA D9S1805 allele was clearly
demonstrated in two homozygous and one compound heterozy-
gous patient. Although the parental DNA samples were not
available for the other compound heterozygous patients, all these
patients were heterozygous for the 19-CA D9S1805 allele. These
data strongly indicate that the IVS12_3insT alleles originate
from an ancestral mutational event.
Taken together, the prevalence of the IVS12_3insT muta-
tion and the cluster of mutations in exons 13, 16, and 17 would
allow identification of most patients with DNAI1 mutations.
Specifically, 21 of all 22 unrelated patients described in the pres-
ent and past studies (24–26) that carry mutations of DNAI1
would be detected by screening for IVS12_3insT and mutations
in exons 13, 16, and 17. This suggests that the development of
clinical molecular genetic testing is a realistic and useful goal.
Similar data are available for another gene encoding an ODA
protein, DNAH5 (28), which has a frequency of mutation in all
PCD of 28% (38 of 134 unrelated families with PCD). Moreover,
in 47% of all mutant DNAH5 alleles (31 of 66), the mutations
were located in clusters of five exons. Combining the data for
both genes (DNAI1 or DNAH5), it seems that approximately
38% of all the patients with PCD are estimated to carry muta-
tions in DNAI1 (22 families) or DNAH5 (38 families). For feasi-
bility of genetic screening, it is important to note that over half
(66 of 108) of the mutant alleles for both genes fall into the
mutation cluster of four exons in DNAI1 and five exons in
DNAH5. Thus, screening for only these nine exons would permit
detection of 41 of 60 (68%) families that harbor mutations in
at least one allele. A reasonable approach for developing a
clinical test panel would be to test by “tiered” approach, for
example, screening for mutation cluster region of the DNAI1
and DNAH5 in phase I, followed by full gene sequencing of the
appropriate gene for the patients with monoallelic mutations in
a second phase. Such genetic analysis would help expedite and
improve the diagnosis of PCD and subsequent counseling for
patients and families.
In conclusion, we show that mutations in DNAI1 are esti-
mated to occur in up to 14% of patients with PCD and reflect
an autosomal recessive mode of inheritance. Most mutations
in DNAI1 are truncating mutations and seem to occur more
commonly in patients with Caucasian ethnicity. These data, cou-
pled with the data for DNAH5 mutations (28), indicate that
development of a clinical molecular genetic panel is feasible and
would improve diagnosis and counseling for PCD.
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